STOCKHOLM, Jan. 15, 2018 /PRNewswire/ --Moberg Pharma AB
(OMX: MOB) have received a positive outcome from the NAD (National
Advertising Division) regarding a challenge filed on Fungi-Nail,
the largest U.S. competitor to the Kerasal Nail®product. NAD
recommends the advertiser to discontinue current product packaging
and commercials. Moberg Pharma expects the outcome to further
strengthen Kerasal Nails®position and growth prospects in
the U.S. market.
In the spring of 2017, Moberg Pharma filed a challenge to NAD on
claims made by Kramer Laboratories, Inc. as for the Original
Fungi-Nail Toe & Foot Brand ("Fungi-Nail Toe & Foot") and
Fungi-Nail Nailner. The challenge mainly concerned product
packaging, television and print advertising for "Fungi-Nail Toe
& Foot"; claiming to treat toenail fungus rather than athlete's
foot which is the approved indication for the product.
A more detailed description of NAD's rationale and conclusion on
the challenge is available in a press release from ASRC, please see
http://www.asrcreviews.org/nad-refers-advertising-for-fungi-nail-products-to-ftc-for-further-review-after-company-declines-to-comply-with-nad-recommendations/.
The press release sets forth NAD's conclusions:
- NAD recommended the advertiser to discontinue the Fungi-Nail
Toe & Foot product name and the associated fungal toenail
images.
- NAD also recommended the Fungi-Nail Toe & Foot product
packaging and television commercials to be discontinued or modified
to clearly and conspicuously state, in proximity to the main
advertising claims, that the product treats athlete's foot, not
toenail fungus.
- NAD recommended the advertiser to discontinue all claims that
the Fungi-Nail Toe & Foot product works "fast," kills fungus
"on contact," stops "tough" infections, and is the "#1 Pharmacist
Recommended" brand. However, NAD found that there is a reasonable
basis for the advertiser's "stops the spread" (of the skin fungus)
claim.
- With respect to the advertiser's Fungi-Nail Nailner product,
NAD recommended the image of the fungal toenail, as well as the
claims: "Clears nails fast," "Visible results after seven days,"
"Looking to improve nail appearance fast? These cure fungus ugly
nails in 48 weeks," and "Fungus Ugly to Prettier Nails Fast!" to be
discontinued.
According to NAD, Kramer Laboratories have declared that they
will comply with all recommendations except for changing the trade
name. As a result, NAD has referred the trade name issue to the
attention of the appropriate government agency for possible
enforcement action.
"We are highly pleased with the outcome from NAD and we
expect the outcome to further strengthen Kerasal Nails® position
and growth prospects in the U.S. market", says Peter Wolpert, CEO of Moberg Pharma AB.
About this information
Moberg Pharma AB is obliged to make this information public
pursuant to the EU Market Abuse Regulation (MAR). The information
was submitted for publication, through the agency of the contact
person set out above, at 08:30 a.m.
(CET) on January 15th,
2018.
For more information, please contact:
Peter Wolpert, CEO
Phone: +1-908-432-22-03 (US), +46-70-735-71-35
e-mail: peter.wolpert@mobergpharma.se
Anna Ljung, CFO
Phone: +46-70-766-60-30
e-mail: anna.ljung@mobergpharma.se
This information was brought to you by Cision
http://news.cision.com
http://news.cision.com/moberg-pharma/r/moberg-pharma-receives-favorable-outcome-from-nad---main-competitor-to-discontinue-current-marketing,c2430893
The following files are available for download:
http://mb.cision.com/Main/1662/2430893/777098.pdf
|
Moberg Pharma
receives favorable outcome from NAD â€" main competitor to
discontinue current marketing
|
View original
content:http://www.prnewswire.com/news-releases/moberg-pharma-receives-favorable-outcome-from-nad--main-competitor-to-discontinue-current-marketing-300582425.html
SOURCE Moberg Pharma